INFevo

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

INFevo - overview

Established

2025

Location

Beijing, Beijing, China

Primary Industry

Biotechnology

About

Based in Beijing, China, and founded in 2025, Beijing Infinite Evolution Technology Co. , Ltd. , trading under the name INFevo, was established as an internally incubated project of XtalPi Inc. The company focuses on applying AI and system biology approaches to support drug research and development, leveraging interdisciplinary expertise in biology, data science, and engineering.


The firm also co-develops the Beijing Key Laboratory of Hepatobiliary and Pancreatic Tumor Organoid Culture and Intelligent Diagnosis and Treatment in collaboration with Peking University First Hospital. In November 2026, the company closed a pre-series A funding round co-led by Link-X Capital, Aramco Ventures, Huagai Capital, T- Capital and Detong Capital. The company develops AI-based virtual cell models and integrates them with automated experimental platforms to support biological research and drug discovery. Its platform combines proprietary foundation models with cellular-level simulations and system biology analysis to enable target discovery, virtual drug screening, and clinical research optimization.


The solutions are applied in research areas including aging, neurodegenerative diseases, autoimmune diseases, metabolic disorders, and oncology, supporting both early-stage discovery and translational research. The company generates revenue by providing AI virtual cell modeling, computational biology software platforms, and closed-loop target discovery and preclinical evaluation solutions to biopharmaceutical companies, hospitals and research institutions. The company plans to use the pre-series A funding to advance the research and development of its foundational biological models, expand the capacity of its high-throughput automated dry-wet closed-loop infrastructure, and deepen collaborations with global pharmaceutical companies, hospitals, and research institutions to accelerate clinical translation.


Primary Industry

Biotechnology

Sub Industries

Biotechnology, Healthcare

Website

www.infevo.ai

Verticals

Artificial Intelligence, HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.